Esther Rajavelu sold $41k of SPRO
See Remarks at Spero Therapeutics, Inc.. 18,442 shares at an average of $2.20, traded Feb 2, 2026, filed Feb 4, 2026.
Score components
- +15RoleOfficer
- +6Trade size$41k at market
- 0Share of holdings soldSold 1.6% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.4%, 3m +10.5%, 6m -45.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-038184, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | AGrant or award Common Stock | +249,000 | $0.00 | $0 | 1,118,450 | Feb 4, 2026 |
| Feb 2, 2026 | SOpen-market sale Common Stock | -18,442 | $2.20 | $41k | 1,100,008 | Feb 4, 2026 |
| Feb 2, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +498,000 | $0.00 | $0 | 498,000 | Feb 4, 2026 |
Related signals
Other insiders at Spero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | SPROsell Spero Therapeutics, Inc. | Esther Rajavelu See Remarks | $63k 25,240 shares | -2% | |
| 34Weak | Spero Therapeutics, Inc. | Timothy Keutzer Chief Operating Officer | $44k 18,652 shares | -2% | |
| 35Weak | Spero Therapeutics, Inc. | Esther Rajavelu See Remarks | $207k 87,917 shares | -8% | |
| 38Weak | Spero Therapeutics, Inc. | Timothy Keutzer Chief Operating Officer | $101k 46,586 shares | -6% | |
| 25Weak | SPROsell Spero Therapeutics, Inc. | Esther Rajavelu See Remarks | $95k 40,270 shares | -4% | |
| 28Weak | Spero Therapeutics, Inc. | Timothy Keutzer Chief Operating Officer | $3,339 1,695 shares | -0% | |
| 23Weak | Spero Therapeutics, Inc. | Ankit Mahadevia director | $13k 6,572 shares | -1% | |
| 26Weak | SPROsell Spero Therapeutics, Inc. | Timothy Keutzer Chief Operating Officer | $44k 56,537 shares | -7% | |
| 29Weak | SPROsell Spero Therapeutics, Inc. | Esther Rajavelu CFO & CBO | $53k 40,596 shares | -10% | |
| 36Weak | Spero Therapeutics, Inc. | Kamal Hamed Chief Medical Officer | $38k 28,075 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.